Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative e...
Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines
About this item
Full title
Author / Creator
Publisher
England: Taylor & Francis
Journal title
Language
English
Formats
Publication information
Publisher
England: Taylor & Francis
Subjects
More information
Scope and Contents
Contents
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast, colon, and prostate subtypes. Herein, new TAK-285 derivatives (9a-h) were synthesised, characterised, and biologically evaluated as dual EGFR/HER2 inhibitors. Compound 9f exhib...
Alternative Titles
Full title
Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10132233
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10132233
Other Identifiers
ISSN
1475-6366
E-ISSN
1475-6374
DOI
10.1080/14756366.2023.2202358
